Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: A randomized controlled trial

Obstetrics and Gynecology

Volumn 124, Issue 4, 2014, Pages 735-742

  Oliveira, Lauren G ^b   Capp, Shannon M ^a   You, Whitney B ^a   Riffenburgh, Robert H ^a   Carstairs, Shaun D ^a  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYLAMINE; ONDANSETRON; PLACEBO; PYRIDOXINE; ANTIEMETIC AGENT;

ADULT; ANESTHESIA COMPLICATION; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HUMAN; HYPERSALIVATION; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PREGNANCY; PREGNANCY DISORDER; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEDATION; VISUAL ANALOG SCALE; XEROSTOMIA; COMPARATIVE STUDY; DRUG COMBINATION; HYPEREMESIS GRAVIDARUM; MORNING SICKNESS; NAUSEA; PATHOPHYSIOLOGY; PATIENT SATISFACTION; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VOMITING; YOUNG ADULT;

ADULT; ANTIEMETICS; DOUBLE-BLIND METHOD; DOXYLAMINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPEREMESIS GRAVIDARUM; MORNING SICKNESS; NAUSEA; ONDANSETRON; PATIENT SATISFACTION; PREGNANCY; PYRIDOXINE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VOMITING; YOUNG ADULT;

EID: 84922367224     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000479     Document Type: Article

References (22)

1. Niebyl J. Nausea and vomiting in pregnancy. N Engl J Med 2010;363:1544-50.
2. Ebrahimi N, Maltepe C, Einarson A. Optimal management of nausea and vomiting of pregnancy. Int JWomen's Health 2010; 2:241-8.
3. Festin M. Nausea and vomiting in early pregnancy. Clin Evid 2009;2009:pii 1405.
4. Lombardi D, Istwan N, Rhea D, O'Brien J, Barton J. Measuring outpatient outcomes of emesis and nausea management in pregnant women. Manag Care 2004;13:48-52.
5. Mazzotta P, Stewart D, Atanackovic G, Koren G, Magee L. Psychosocial morbidity among women with nausea and vomiting of pregnancy: prevalence and association with antiemetic therapy. J Psychosom Obstet Gynaecol 2000;21:129-36.
6. Badell M, Ramin S, Smith J. Treatment options for nausea and vomiting during pregnancy. Pharmacotherapy 2006;26: 1273-87.
7. Magee L, Mazzotta P, Koren G. Evidence-based review of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy (NVP). Am J Obstet Gynecol 2002;186:S256-61.
8. Matthews A, Dowswell T, Haas D, Doyle M, O'Mathúna D. Interventions for nausea and vomiting in early pregnancy. The Cochrane Database of Systematic Reviews 2010, Issue 9. Art. No.: CD007575. doi: 10.1002/14651858.CD007575.pub2.
9. Nausea and vomiting of pregnancy. ACOG Practice Bulletin No. 52. American College of Obstetricians and Gynecologists. Obstet Gynecol 2004;103:803-16.
10. Kutcher J, Engle A, Firth J, Lamm S. Bendectin and birth defects. II: Ecological analyses. Birth Defects Res A Clin Mol Teratol 2003;67:88-97.
11. Meek R, Kelly A, Hu X. Use of the visual analog scale to rate and Monitor severity of nausea in the emergency department. Acad Emerg Med 2009;16:1304-10.
12. Tanen DA, Miller S, French T, Riffenburgh RH. Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial. Ann Emerg Med 2003;41: 847-53.
13. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:4112-9.
14. Vutyavanich T, Wongtra-ngan S, Ruangsri R. Pyridoxine for nausea and vomiting of pregnancy: a randomized, doubleblind, placebo-controlled trial. Am J Obstet Gynecol 1995; 173(3 pt 1):881-4.
15. Einarson TR, Leeder JS, Koren G. A method for meta-analysis of epidemiological studies. Drug Intell Clin Pharm 1988;22: 813-24.
16. McKeigue PM, Lamm SH, Linn S, Kutcher JS. Bendectin and birth defects: I. a meta-analysis of the epidemiologic studies. Teratology 1994;50:27-37.
17. Siu S, Yip S, Cheung C, Lau T. Treatment of intractable hyperemesis gravidarum by ondansetron. Eur J Obstet Gynecol Reprod Biol 2010;105:73-4.
18. Sullivan C, Johnson C, Roach H, Martin R, Stewart D, Morrison J. A pilot study of intravenous ondansetron for hyperemesis gravidarum. Am J Obstet Gynecol 1996;174:1565-8.
19. Tincello D, Johnstone M. Treatment of hyperemesis gravidarum with the 5-HT3 antagonist ondansetron (Zofran). Postgrad Med J 1996;72:688-9.
20. Pasternak B, Svanstrom H, Hviid A. Ondansetron in pregnancy and risk of adverse fetal outcomes. N Engl J Med 2013;368: 814-23.
21. U.S. Food and Drug Administration. FDA drug safety communication: new information regarding QT prolongation with ondansetron (Zofran). Available at: http://www.fda.gov/Drugs/DrugSafety/ucm310190.htm. Retrieved May 26, 2014.
22. CardinalHealth. Ohio: pharmaceutical distribution; c2010-11. Available at: http://www.cardinalhealth.com/. Retrieved July 9, 2013.